ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Advocacy
  • Anal cancer
  • Artificial intelligence (AI)
  • Bladder cancer
  • Brain cancer
  • Breast cancer
  • Colorectal cancer
  • ComboMATCH
  • Esophagus cancer
  • Gallbladder cancer
  • Head and neck cancer
  • Health equity
  • Immunotherapy
  • In memory
  • Kidney cancer
  • Leukemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Melanoma
  • Myelodysplastic syndrome
  • Myeloma
  • NCI-MATCH
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Penis cancer
  • Personalized treatment
  • Policy
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Real-world data/evidence
  • Research results
  • Sarcoma
  • Screening for cancer
  • Side effects
  • Survivorship
  • Targeted therapy
  • Upper tract urothelial cancer
  • Young adults
March 26, 2024
March 26, 2024
Categories
  • New Trials

Now Enrolling: ComboMATCH treatment trial E5 is testing a new option for patients with advanced solid tumors that have a KRAS G12C mutation

This study is assessing the combination of two drugs—sotorasib and panitumumab—in patients with KRAS G12C-mutated solid tumors
Do you like it?
0 Read more
March 26, 2024
March 26, 2024
Categories
  • Ongoing Trials

Ongoing Trial: The EA8192 clinical trial is testing a new treatment approach for patients with upper tract urothelial cancer

This study is for patients with cancer in the lining of the kidney or the tube that connects the kidney to the bladder
Do you like it?
0 Read more
March 26, 2024
Research dictionary entry
March 26, 2024
Categories
  • Trial Results

Trial Results: ECOG-ACRIN research round-up – Spring 2024

Summaries of recent publications by researchers affiliated with ECOG-ACRIN
Do you like it?
0 Read more
January 22, 2024
January 22, 2024
Categories
  • New Trials

Now Enrolling: The EA3211 study is evaluating a new treatment strategy for certain patients with head and neck cancer

This study is for patients with head and neck squamous cell carcinoma that has spread to just a few other areas in the body
Do you like it?
0 Read more
Prev page
123456789101112131415161718
Next page

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2026 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc